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ScienceDirectGold compounds for catalysis and metal-mediated
transformations in biological systems
Sophie R. Thomas1 and Angela Casini1,2Abstract
One of the challenges of modern inorganic chemistry is
translating the potential of metal catalysts to living systems to
achieve controlled non-natural transformations. This field
poses numerous issues associated with the metal compounds
biocompatibility, stability, and reactivity in complex aqueous
environment. Moreover, it should be noted that although
referring to ‘metal catalysis’, turnover has not yet been fully
demonstrated in most of the examples within living systems.
Nevertheless, transition metal catalysts offer an opportunity of
modulating bioprocesses through reactions that are comple-
mentary to enzymes. In this context, gold complexes, both
coordination and organometallic, have emerged as promising
tools for bio-orthogonal transformations, endowed with excel-
lent reactivity and selectivity, compatibility within aqueous re-
action medium, fast kinetics of ligand exchange reactions, and
mild reaction conditions. Thus, a number of examples of gold-
templated reactions in a biologically relevant context will be
presented and discussed here in relation to their potential
applications in biological and medicinal chemistry.
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The use of metal complex catalysts within living bio-
logical systems is an area of research that has recentlywww.sciencedirect.comgained significant attention [1e6]. Metal-mediated re-
actions have potential use for biological sensing, imag-
ing, and caging applications, as well as for therapy.
Certainly, the peculiar reactivity and selectivity of
metal-based complexes significantly broadens the scope
of the chemical reaction toolbox for biomolecule modi-
fication. Current examples of metal-catalysed reactions
in biological settings and of therapeutic relevance
include redox-active transition metal complexes that
can be used to promote the formation of reactive oxygen
species or metal-bound oxygen species, responsible for
subsequent oxidative damage to biological targets [7e
9], and that are regenerated through electron transfer
from intracellular reducing biomolecules [10]. In this
category of reactive oxygen speciesegenerating com-
pounds, metal complexes producing singlet oxygen
inside cells upon irradiation with light (photodynamic
therapy, PDT) are relevant, with some examples already
close to clinical application [11].
In addition to redox processes, the chemistry of transi-
tion metal complexes has been rapidly expanding to
other types of transformations in living conditions,
including cross-coupling reactions [12e14], cycloaddi-
tions [15], hydrogenation and transfer hydrogenation
reactions [16,17], or functional group deprotection
(uncaging) reactions [18e21]. It is worth mentioning
that the past decade witnessed new ways of tagging
proteins with fluorophores or other probes based on
metal-templated mechanisms including the Suzukie
Miyaura, MizorokieHeck and Sonogashira cross-
coupling reactions [4,5,22]. In this context, palladium
compounds occupy a pivotal role [5]. Although the field
is dominated by homogenous metal-based compounds,
heterogeneous Pd catalysts hold promise [23,24], with
potential for in vivo application. Recent work in the
metal promoted CeH functionalization of nucleobases
in aqueous media might also lead to future biological
applications [25]. All these processes can be exploited
for therapy, both to deactivate relevant pharmacological
targets and to induce intracellular redox damage, or for
prodrug activation in situ, as well as for bio-orthogonal
modifications of biomolecules in physiological environ-
ment enabling studies of biochemical interactions on
the single-molecule level.
Recently, some examples have appeared concerning the
use of gold compounds for selective modifications ofCurrent Opinion in Chemical Biology 2020, 55:103–110
104 Bioinorganic chemistrybiomolecules via CeC or C-X (X = heteroatom) bond
formation for different applications in biological sys-
tems. This is not surprising because the power of gold
catalysis also stems from the ability of gold cationic
complexes to coordinate and activate unsaturated bonds
in a chemoselective manner [26e28]. In this review, we
will critically present various examples of gold-
templated reactions, illustrating the compounds’
design concept and proposed mechanisms, as well as the
advantages with respect to other metal-mediated ap-
proaches. Reports on the selective sensing of ‘free’ gold
ions in cells will be included, in which the ability of
AuIII/AuI ions to promote cyclization and fluorescence
activation of organic molecules containing alkyne groups
is exploited. The use of gold-mediated cross-coupling
reactions for selective modification of proteins will also
be discussed. Furthermore, examples of catalytic gold
complexes and their potential therapeutic applications
will be highlighted.Gold compounds for metal-mediated bio-
orthogonal modifications and catalysis in
cells
To the best of our knowledge, the first report of gold
compounds as catalysts in biological conditions was
published by Jou et al. in 2009, [29**] when a
rhodamineealkyne derivative was investigated as a se-
lective fluorescence sensor d ‘chemodosimeter’ d for
AuIII ions. In detail, the AuIII ions mediated the intra-
molecular cyclization of the propargylamide moiety on
the rhodamine derivative to an oxazolecarbaldehyde
moiety (Figure 1, Table 1). This instigated over 100-fold
enhancement in the substrate fluorescence and induced
a colorimetric change to pink from colourless [29**].
This effect was also previously observed in the presence
of Pd2þ salts; however, addition of stoichiometric
amount of an oxidant was required in this latter case
[30]. The selectivity of the sensor was evaluated in the
presence of a variety of metal ions, including divalent
cations of the transition metal series and alkaline and
alkaline earth ions; however, fluorescence was producedFigure 1
AuIII-induced cyclization from propargyla
Current Opinion in Chemical Biology 2020, 55:103–110only in the presence of AuIII ions, illustrating its
exceptional selectivity [29**]. To elucidate the appli-
cability of the rhodamineealkyne probe in living sys-
tems, the reaction was investigated by fluorescence live
cell imaging using HaCaTcells (human keratinocyte cell
line). The cells were first incubated with the non-fluo-
rescent probe (20 mM) for 2 h and then with AuCl3
(10 mM) for 1 h. Confocal microscopy images showed
intracellular localization of the fluorescence, demon-
strating the potential of the probe for applications in
biological systems [29**]. In the same year, Yang et al.
[31] published a similar work describing the use of a
slightly different rhodamine derivative that could act as
a probe for AuIII ions (Table 1). As in the previous
example, the irreversible AuIII-promoted cyclization of
the nonfluorescent rhodamine amide tethered with an
alkyne to a highly fluorescent compound was observed
by fluorescence spectroscopy and microscopy in cells
[31].
An alternative AuIII ion sensor was published one year
later by Do et al. [34**] based on an apo-coumarin
scaffold rather than the propargylamide-derived rhoda-
mine previously reported [[29**], [31]]. The latent
apo-coumarin fluorophore contained a dialkylamino
group in para position to the Michael acceptor, favouring
the AuIII-mediated hydroarylation [34**]. The cycliza-
tion reaction via CeC bond formation led to a marked
increase in fluorescence which could be observed also in
HaCaT cells (Table 1) [34**].
After a similar carbocyclization approach, in 2018 Vidal
et al. [41**] attempted the AuI-mediated hydro-
arylation of a pro-coumarin substrate, resulting in a
highly fluorescent coumarin product (Table 1). In this
case, coordination complexes of the type [AuI(L)Cl]
(L = phosphane ligand) were used. Thus, the complex
[Au(PTA)Cl] (PTA = 1,3,5-triaza-7-
phosphaadamantane) (5 mol%) was tested and the re-
action, performed in water/acetonitrile (20% vol) at
37 C, resulted in excellent yields [41**]. Afterwards,Current Opinion in Chemical Biology
mide to oxazolecarbaldehyde [29**].
www.sciencedirect.com
Table 1
Gold complex–mediated reactions in biological systems.
Transformation Catalyst Biological system Year Reference
Heterocyclization
oxa-cyclizations
AuIII
HaCaT (cells) 2009 [29**]
HeLa (cells) 2009 [31]
N2A (cells) 2014 [32*]
hydroamination
HeLa (cells) 2012 [33]
Carbocyclization
hydroarylation
HaCaT (cells) 2010 [34**]
Cysteine Arylation
BSA and HSA (protein) 2014 [35**]
DARPin and FGF2 (protein) 2018 [36**]
ZF-NCp7 (peptide) 2018 [37*]
ZF-Cys2His2 (peptide) 2019 [38**]
Ester Amidation
Mouse (animal) 2017 [39**]
(continued on next page)
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Table 1 (continued )
Transformation Catalyst Biological system Year Reference
Cyclization
oxa-cyclizations
AuI
A549 (cells) 2012 [40*]
hydroarylation
HeLa (cells) 2018 [41**]
BSA, bovine serum albumin; HSA, human serum albumin; FGF2, fibroblast growth factor 2; ZF, zinc finger; DARPin, designed ankyrin repeat protein.
106 Bioinorganic chemistrythe performance of other water soluble AuI complexes
with different phosphane ligands were investigated, also
producing the carbocyclization product in very high
yields [41**]. The mechanistic hypothesis evidenced
the importance of the hydrolysis of the chlorido ligands
to foster the desired catalytic reactivity. In this study,
AuIII complexes or salts were only scarcely reactive.
Fluorescent microscopy images were then obtained for
HeLa (cervical cancer) cells treated with [Au(PTA)Cl]
(50 mM, 30 min) and the pro-coumarin substrate
(100 mM, 6 h), resulting in the fluorescent coumarin
product accumulating in lysosomes after 6 h incubation
[41**].
Unfortunately, the presence of excess thiols such as
glutathione and cysteine, typically found in physiolog-
ical conditions, led to a marked inhibition of the cata-
lytic ability of [Au(PTA)Cl], most likely due to the
competitive binding of the thiols to the gold [41**].
Therefore, these types of complexes may have scarce
chances to be catalytically active in vivo unless properly
targeted to cancer tissues and protected from specia-
tion. Of note, this work also included a concurrent Ru-
mediated deallylation reaction alongside the Au-
mediated hydroarylation, with the same substrates
[41**]. Infrared fluorescence was observed for the
deallylation product, whereas the hydroarylation prod-
uct produced green and blue emission as seen previ-
ously. This is the first example of concurrent and
orthogonal Au/Ru-mediated intracellular reactions,
providing an initial step towards the production of arti-
ficial metabolic networks mediated by metals [41**].
Over the years, different probes for gold ions’ sensing in
cells were developed, including molecules which un-
derwent heterocyclization reactions (with AuIII ions)Current Opinion in Chemical Biology 2020, 55:103–110within a fluorescence resonance energy transfer system
[32*], as well as intramolecular hydroamination (for both
AuI and AuIII sensing) (Table 1) [33]. In 2012, a different
approach was reported by Patil et al. [40*] involving the
‘anchoring and unanchoring’ of a fluorophore for gold
sensing (Table 1), whereby, in a first step, upon addition
of a fluorescentmolecule to an organic substrate,masking
of the fluorescence was observed. In the presence of AuI
ions (and AuIII, although at a slower rate), the fluorescent
probe is released producing an intense fluorescence
signal. When A549 cells (lung cancer cell line) were
incubated with the sensor and AuI ions, green fluores-
cence appeared intracellularly [40*].
Gold compounds have also been explored as catalysts for
selective bio-orthogonal modifications of proteins in
living cells. This stemmed from the success of PdII
complexes, including the studies by Vinogradova et al.
[42] concerning the arylation of cysteine residues, which
are, nevertheless, still hampered by unwanted in-
teractions with endogenous functional groups in cells.
This lead to interest in gold complexes owing to their
compatibility with catalysis in aqueous environment,
mild reaction conditions, chemoselectivity and fast ki-
netics of ligand exchange reactions [43,44].
In 2014, Kung et al. [35**] were the first to publish on
the use of cyclometalated AuIII complexes for the
arylation of cysteine via CeS bond forming reductive
elimination (Table 1, Figure 2). This approach was
proposed as an alternative to the prevalent N-methyl-
maleimide cysteine ligation, which suffered with lack of
stability in physiological conditions [22]. In detail, the
modular synthesis of four cyclometalated AuIII C^N
complexes was reported, including [Au(CCH2N)msen]
(CCH2N = 2-benzylpyridine; msen = N,N0-www.sciencedirect.com
Figure 2
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a
b
Gold templated C-S cross-coupling reaction with peptides. (a) Representative organometallic AuIII complexes studied for Cys-arylation. (b) Mech-
anisms of Cys-arylation via reductive elimination mediated by cyclometalated AuIII C^N complexes with Cys residues [35**–38**].
Challenging gold catalysis for therapy and imaging Thomas and Casini 107bis(methanesulfonyl)ethylenediamine) (Figure 2),
which mediated cysteine arylation in good yields via
reductive elimination when treated with different
cysteine containing peptides in phosphate buffered
saline (PBS, pH 7.4): DMSO (9:1) solution at 25 C for
2 h, as confirmed by liquid chromatography-mass spec-
trometry (LC-MS).[35**]. The [Au(CCH2N)Cl2] (1,
Figure 2) derivative was also studied, and showed poor
cysteine chemoselectivity, evidencing the need for the
‘soft’ chelating msen ligand to be displaced by ‘soft’
thiol groups of cysteine forming an initial coordination
adduct before reductive elimination. The [Au(phepy)
msen] (phepy = 2-phenyl-pyridinate) derivative was
not able to give CeS cross-coupling with Cys residues
but could only form [Au(phepy)-Cys] adducts [35**].
Furthermore, a cyclometalated AuIII C^N dansyl-
functionalised cyclometalated compound was incu-
bated with bovine serum albumin and human serum
albumin in PBS:DMSO (9:1) at 37 C for 24 h [35**].
Selective arylation of the single, surface-exposed
cysteine in both proteins was successful, as shown by
liquid chromatography-tandem mass spectrometry (LC-
MS/MS), demonstrating the possibility of protein
modifications in biological systems [35**].
In 2018, Messina et al. [36**] were next to report on
AuIII-mediated cysteine arylation. In this work, 3 equiv-
alent of an oxidative addition complex [(Me-DalPhos)
Au(tolyl)Cl][SbF6] (Me-DalPhos = adamantyl2P(o-
C6H4)NMe2, Figure 2) showed quantitative arylation ofwww.sciencedirect.comglutathione at 25 C in H2O: MeCN (80:20) after a few
minutes. The gold-mediated reaction was compatible
with a large pH range, several buffers, the disulfide
reducing agent tris(2-carboxyethyl)phosphine and the
protein denaturing agent (guanidineHCl) [36**]. De-
rivatives of the lead compound able to perform CeS
cross-coupling reaction with complex peptide sub-
strates were also prepared by replacing the tolyl group
with biorelevant moieties such as heterocycles, an af-
finity label fluorescent tag, a drug molecule and a poly(-
ethylene glycol) polymer [36**].
The biocompatibility of the organometallic AuIII system
was demonstrated further by cysteine arylation of
designed ankyrin repeat protein and fibroblast growth
factor 2, as observed by LC-MS analysis [36**]. After-
wards, the AuIII compound was challenged against a
comparable PdII complex reported for cysteine arylation
[42], with respect to GSH arylation [36**]. The results
showed ca. 92% conversion to the Au-mediated conju-
gate, indicating that substrate arylation occurred at a
quicker rate than the palladium-mediated arylation
[36**].
The success of gold-mediated cysteine arylation by
[AuIII(CCH2N)Cl2] (1, Figure 2) was confirmed by de
Paiva et al. [37*], observing the reaction in zinc finger
(ZF) protein domains by MS. Of note, in this case,
reductive elimination was observed only in reaction
conditions far from the physiological ones and after 48 hCurrent Opinion in Chemical Biology 2020, 55:103–110
108 Bioinorganic chemistryincubation [37*]. Moreover, classical AuIII complexes
with bidentate N-donor ligands were ineffective with
respect to Cys arylation, although able to form Au-ZF
adducts.
Inspired by these results, our group recently expanded
the library of AuIII cyclometalated (C^N) complexes
capable of cysteine arylation, including 1, complex
Au(CNHN)Cl2 (2, C
NHN = N-phenylpyridin-2-amine)
and Au(CCON)Cl2 (3, C
CON = 2-benzoylpyridine)
(Figure 2) [38**]. Each compound was incubated with a
model ZF peptide of the Cys2His2 type in (NH4)2CO3
buffer (pH 7.4) at 37 C for 10 min and 24 h, samples
were then analysed by high-resolution LC electrospray
ionization MS [38**]. All the compounds initially
formed classical apo-ZF-[AuIII(C^N)] adducts following
chlorido ligands’ hydrolysis, as previously demonstrated
with different ZFs [45], but the reaction eventually
progressed, although at different rates, towards the
formation of apo-ZF-[C^N] adducts, indicative of CeS
cross-coupling via reductive elimination [38**].
To elucidate the mechanism leading to reductive elim-
ination and to draw initial structure activity relation-
ships, DFT (density functional theory) calculations
were performed on the reaction of the complexes with
two cysteinate ligands used as models [38**]. Thus, a
reaction mechanism was proposed, whereby the first
cysteinate binds trans to the N and the second one is
needed to favour the bond breakage between the ni-
trogen and the AuIII centre forming the intermediate
[AuIII(C^N)(Cys)2Cl]
-. This enables rotation of the arylFigure 3
In vivo gold catalyzed reaction. (a) Structure of the Au-coumarin conjugate
complexes and mechanism of reactivity. (b) Time-course imaging of liver- and
view) treated with (a) glycoalbumin (Sia) followed by Cy7.5-OProp as a contr
followed by Cy7.5-OProp. The Glyco-Au complexes (3.4 nmol) or glycoalbumin
tail vein (N = 6). After 30 min, Cy7.5-OProp or TAMRA-OProp (5.0 nmol) was
isoflurane and placed in a fluorescence imager, where images were taken at 3
paraformaldehyde solution, and the fluorescence intensity in the liver was sub
et al. [39**].
Current Opinion in Chemical Biology 2020, 55:103–110group, allowing reductive elimination to take place
forming the Cys-arylated product and the [CysAuICl]-
side complex. The calculated relative standard free
Gibbs energy values provided a possible explanation for
the increased ability of Au(CCON)Cl2 to perform
reductive elimination compared with Au(CCH2N)Cl2
and even more so Au(CNHN)Cl2. In detail, the activa-
tion barrier for the CeS coupling increases in the order
3 < 1 < 2, following the same trend as the experimental
reductive elimination reaction rate [38**].
In 2017, the first in vivo study on a gold-templated re-
action was published by Tsubokura et al. [39**],
whereby a AuIII cyclometalated compound conjugated
to coumarin was capable of activating propargyl esters
featuring another fluorophore (Table 1, Figure 3). In this
case, AuIII-mediated amide bond formation occurs be-
tween the propargyl ester probes and nearby protein-
surface amines. The work exploited the use of organ-
targeting glycoalbumins which acted as carriers for the
Au-coumarin catalyst owing to the strong binding af-
finity between the hydrophobic coumarin and the
binding pocket of albumin [[39**], [46]]. The com-
pound enabled localization in specific organs in mice by
fluorescence imaging (Figure 3), providing the proof of
concept for a more therapeutically viable Au catalyst
[39**].Summary and perspectives
The use of transition metal catalysis within living sys-
tems is nontrivial, due to stability, efficiency andand schematic representation of the Glyco-Au (Gal) and Glyco-Au (Sia)
intestine-selective fluorescence labelling of BALB/c nude mice (abdominal
ol, (b) Glyco-Au (Sia) followed by Cy7.5-OProp, and (c) Glyco-Au (Gal)
control were injected into 8–10 week old BALB/cAJcl-nu/nu mice via the
injected into the mice. They were then anesthetized with pentobarbital or
0-min intervals. After 2 h, the mice were sacrificed and perfused with 4%
sequently measured. Adapted with permission from a study by Tsubokura
www.sciencedirect.com
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field has gained importance over the past few years and
provided a number of promising examples. In this
context, gold-promoted reactions represent a significant
addition to the toolbox of life compatible trans-
formations. As discussed here, recent reports explore
gold compounds for a number of metal-mediated bio-
orthogonal transformations in living systems, specifically
aiming at producing novel chemical tools and thera-
peutic agents. Although until now the few available
examples suffer from the side reactivity of the AuI/AuIII
complexes with biomolecules and intracellular reducing
agents which prevent their catalytic action, in the near
future this could be overcome by fine-tuning the com-
pounds’ redox and nucleophilic properties via judicious
choice of the ligand system. For example, different
families of organometallic gold complexes, endowed
with improved stability and robustness of functionali-
zation, could be explored, including AuI N-heterocyclic
carbenes and alkynyl complexes, as well as cyclo-
metalated AuIII compounds [47,48]. This strategy has
already been exploited in classical medicinal inorganic
chemistry, where organometallic gold compounds have
shown promising anticancer properties in vitro and in vivo
[48]. Furthermore, the incorporation of the gold cata-
lysts into engineered nanometric scaffold (to achieve so-
called ‘nanozymes’) could be envisaged, with the aim of
enhancing their water solubility and to provide protec-
tion from speciation in vivo [49*].Conflict of interest statement
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